1. INDIRECT TREATMENT COMPARISON OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE FOR RELAPSED AND REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA USING TIME-VARYING HAZARD RATIOS

被引：0
|
作者：
Wu, E. [1 ]
Keeping, S. [2 ]
Chan, K. [2 ]
Mojebi, A. [2 ]
Balakumaran, A. [1 ]
机构：
[1] Merck, N Wales, PA USA
[2] Precis Xtract, Vancouver, BC, Canada
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1510
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM79
引用
收藏
页码：S223 / S223
页数：1
相关论文
共 17 条
  • [1] Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison
    Keeping, Sam
    Wu, Elise
    Chan, Keith
    Mojebi, Ali
    Ferrante, Shannon Allen
    Balakumaran, Arun
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (06) : 503 - 511
  • [2] Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective
    Large, Samuel
    Hettle, Robert
    Balakumaran, Arun
    Wu, Elise
    Borse, Rebekah H.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 16 - 25
  • [3] Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Jimenez-Ubieto, Ana
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Nunes, Ana
    Reitan, John
    Wade, Sally W.
    Salles, Gilles
    LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 14 - 25
  • [4] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN (BV) IN ADULT AND PAEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA IN FRANCE
    Minacori, R.
    Apert, M.
    Leproust, S.
    Monnier, R.
    Casasnovas, R. O.
    Brice, P.
    Borse, R. H.
    Gandhi, J.
    Rai, A.
    VALUE IN HEALTH, 2022, 25 (01) : S55 - S55
  • [5] A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Armand, Philippe
    Rogula, Basia
    Johnston, Karissa
    Peterson, Derek
    Connors, Joseph M.
    Lozano-Ortega, Greta
    BLOOD, 2019, 134
  • [6] Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    Jianming He
    Heather Berringer
    Bart Heeg
    Haoyao Ruan
    Tobias Kampfenkel
    Harikumaran R. Dwarakanathan
    Stephen Johnston
    João Mendes
    Annette Lam
    Sacheeta Bathija
    Emma K. Mackay
    Advances in Therapy, 2022, 39 : 4230 - 4249
  • [7] Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Ruan, Haoyao
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    ADVANCES IN THERAPY, 2022, 39 (09) : 4230 - 4249
  • [8] Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008
    Lavie, David
    Timmerman, John
    Garcia-Sanz, Ramon
    Kim, Won Seog
    Kim, Tae Min
    Avigdor, Abraham
    Dierickx, Daan
    Jagadeesh, Deepa
    Molin, Daniel L.
    Ozcan, Muhit
    Sevindik, Omur Gokmen
    Saeed, Hayder
    Sidi, Yulia
    Pillai, Pallavi
    Marinello, Patricia
    Herrera, Alex F.
    BLOOD, 2023, 142
  • [9] A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
    Kordbacheh, Tiana
    Prica, Anca
    Chan, Kelvin K. W.
    Aminilari, Mahmood
    Ante, Zharmaine
    Liu, Ning
    Gong, Inna Y.
    Bhella, Sita
    Crump, Michael
    Vijenthira, Abi
    Kuruvilla, John
    Kridel, Robert
    Chen, Christine, I
    Kukreti, Vishal
    Yang, Chloe
    Malik, Nauman
    Hodgson, David
    Rodin, Danielle
    BLOOD, 2024, 144 : 5134 - 5135
  • [10] Cost of 90Y-ibritumomab tiuxetan radioimmunotherapy versus cost of standard regimens for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma in Switzerland
    Frei, Andreas
    Delmore, Geoffrey
    Hitz, Felicitas
    Schwenkglenks, Matthias
    Szucs, Thomas
    BLOOD, 2007, 110 (11) : 975A - 975A
12